ÌÇÐÄÊÓÆµlogo

Biodiversity Conservation

Policy and Basic Concept

As a global healthcare company, the ÌÇÐÄÊÓÆµlogo Group has established the ENW (ÌÇÐÄÊÓÆµlogo Network Companies) Environmental Policy and conducts business activities with a focus on global environmental protection. The policy states that we will “6. Contribute to the realization of a society in harmony with nature by developing business activities that take into consideration the conservation of biodiversity” . Accordingly, we are promoting biodiversity conservation initiatives on a global scale.

The ÌÇÐÄÊÓÆµlogo Group conducts its business activities using natural resources supported by biodiversity. The anti-cancer agent Halaven, which was discovered and developed in-house, was derived from the natural product Halichondria okadai and biodiversity conservation is therefore an important consideration for the sustainabity of our business activities. To this end, we have established the ENW Biodiversity Guidelines and share these principles with all directors and employees to promote understanding of the importance of biodiversity and fulfillment of our  responsibilities related to biodiversity.

ENW Biodiversity Guidelines


The ÌÇÐÄÊÓÆµlogo Group is grateful for the blessings of nature produced by biodiversity and strives to conserve biodiversity and use biological resources in a sustainable manner. We will consider the impact of our business activities on biodiversity and contribute to the realization of a society coexisting with nature based on harmony with the global environment.

  
1. We will strive to understand the impact of our business activities on biodiversity not only in the Group companies but also in the entire supply chain, and conduct corporate management that emphasizes the conservation of biodiversity.

 
2. We will actively promote the reduction of greenhouse gas emissions, the prevention of environmental pollution caused by the emission of chemical substances, and the proper disposal of waste as well as the effective use of resources for the purpose of reducing the environmental impact that adversely affects biodiversity.

 

3. We will conduct our business activities in compliance with international laws, regulations, and agreements as well as the fair use of biological resources, including genetic resources to ensure their sustainable use.

 
4. We will raise awareness of our employees regarding the necessity to conserve biodiversity and contribute to the creation of a society that fosters biodiversity through cooperation and collaboration with stakeholders in and outside Japan.

 
5. We will improve our credibility with society through proactive disclosure of environmental information related to the conservation of biodiversity.

 

 

May 30, 2025
Teruyuki Masaka
  

Vice President, Sustainability

ÌÇÐÄÊÓÆµlogo

Targets and Actions

Mapping the Relationships Between ÌÇÐÄÊÓÆµlogo's Business and Biodiversity

In fiscal 2022, the ÌÇÐÄÊÓÆµlogo Group assessed the relationship between our business activities and biodiversity, with reference to “The Business and Biodiversity Interrelationship Map®” developed by the Japan Business Initiative for Biodiversity (JBIB), in order to better understand how our business depends on and impacts biodiversity (See figure below). As a result, no material biodiversity-related risks have been identified at this time. However, we identified the following medium- to long-term risks for ongoing monitoring:

〶Ä

  1. Potential impacts on biodiversity in surrounding areas resulting from emissions to water and air from operating sites.
    The areas surrounding our 13 major operating sites have been identified as areas for ongoing risk monitoring.
    1. *13 major operating sites

      Kawashima Plant (Gifu, Japan), Tsukuba Research Laboratories (Ibaraki, Japan), Kashima Plant (Ibaraki, Japan), Kobe Research Laboratories (Hyogo, Japan), EA Pharma Fukushima Plant (Fukushima, Japan), Suzhou Plant (Jiangsu, China), Benxi Plant (Liaoning, China), Bogor Plant ((Bogor Province, Indonesia), Vizag Site (Andhra Pradesh, India), European Knowledge Center (Hertfordshire, UK), Exton Site (Pennsylvania, USA), Baltimore Plant (Maryland, USA), G2D2 (Massachusetts, USA)

  2. Environmental impact of waste generated from product use (e.g., marine plastic problem)

Mid-term Biodiversity Targets

To promote biodiversity conservation activities, the ÌÇÐÄÊÓÆµlogo Group has established the following mid-term targets, following deliberation and approval by the Company-wide Environment and Safety Committee, chaired by the Corporate Officer for Sustainability. We will continue to monitor the impacts of our business activities on biodiversity and advance our initiatives.


  

FY2025

At major operating sites, identify at least one important species in the vicinity of each site and initiate conservation activities at a minimum of 10 of the 13 major operating sites.

   

FY2030

    • 1. All major operating sites have initiated conservation activities for important species identified in the vicinity of their sites, with conservation efforts ongoing at seven or more sites.

    • 2. Introduce eco-friendly materials for product packaging, etc. (implemented for selected product items)

Structures and Systems

The ÌÇÐÄÊÓÆµlogo Group has established an environmental management system to support its global activities and is strengthening efforts to identify environmental risks and implement countermeasures both in Japan and overseas.

Promotion Structure and Internal Audits of Environmental Management〶Ä

Initiatives

By fiscal 2025, important biological species had been identified at 11 of our 13 major operating sites.
Since beginning operations in March 1966, the Kawashima Plant has worked to preserve the natural environment within the site under the concept of “All for Patients and Nature.” Approximately, 50% of the plant’s 470,000 m2 site area is covered by greenery, and approximately 30,000 trees, including Japanese black pines, are maintained and managed on the premises. In addition, the Medicinal Herbal Garden at the Naito Museum of Pharmaceutical Science and Industry, located within the Kawashima Plant, cultivates and conserves approximately 700 species of medicinal and beneficial plants. The garden also conserves 40 species included in the Ministry of the Environment’s Red List, including near-threatened species. In March 2026, the Medicinal Herbal Garden was certified by the Japan Association of Botanical Gardens as a ‘Biodiversity Conservation Hub Botanical Garden’.

 

At the Kashima Plant, initiatives include restoration of black pine forests and cultivation of Hamakakiran (Epipactis papillosa), a species associated with those forests. EA Pharma’s Fukushima Plant maintains planted forests on its premises, including Somei Yoshino cherries and Weeping cherry trees. In addition, since FY2020, the Vizag site (India) has conducted tree-planting activities to promote environmental awareness and has planted approximately 11,000 trees to date. Furthermore, the Bogor plant (Indonesia), cultivates orchids species protected by the Indonesian government.

Data

biodiversity conservation